Trials / Completed
CompletedNCT03205228
Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors
Treatment Outcomes in Patients With Globus: A Randomized Control Trial of Psychoeducation, Anxiolytics and Proton Pump Inhibitors
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Mahidol University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A randomized controlled trial study is conducted to compare treatment efficacy between psycho-education, anxiolytics drug and proton pump inhibitors in participants who met the criteria of globus.
Detailed description
This is a randomized controlled trial in patients with globus. All participants will be allocated into 3 groups (16 subjects/group) : Proton pump inhibitors (miracid®) , anxiolytics drug (Deanxit®) and psycho-education. The study duration is 4 weeks long. Data regarding clinical severity and quality of life of all participants will be collected at the beginning and at the end of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omeprazole | A capsule of Omeprazole 20 mg \& 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule). |
| BEHAVIORAL | psychoeducation | Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period. |
| DRUG | Flupentixol +Melitracen | A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg \& a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule) |
Timeline
- Start date
- 2017-07-07
- Primary completion
- 2018-06-26
- Completion
- 2018-07-28
- First posted
- 2017-07-02
- Last updated
- 2018-08-22
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT03205228. Inclusion in this directory is not an endorsement.